The available evidence supports sermorelins long-term safety profile: Published Evidence A study in the Journal of Clinical Endocrinology & Metabolism followed elderly subjects receiving nightly GHRH (1-29) injections (sermorelin) and found sustained increases in GH and IGF-1 without significant adverse effects or pituitary desensitization (Vittone et al., 1997)
A higher dose or longer intervention period may lead to more substantial changes in study results
"Determination of blood total, reduced, and oxidized glutathione in pediatric subjects"
MetS affects approximately 125314% of adults worldwide and is associated with chronic low-grade inflammation, oxidative stress and disturbances in tissue metabolism (Reference Peterseim, Jabbour and Kamath Mulki27)
That reflects the type of transparent attribution that FDA's publicly stated concerns around compounded GLP-1 marketing specifically address
Its structure provides strength, elasticity, and structure throughout the body, holding cells and tissues together
